Neutral · 57/100Oct 7, 11:44 AM EDT
Rocket Pharma Outlines Pivotal Path for Danon Disease Gene Therapy RP-A501
RCKT
Rocket Pharmaceuticals announced a clear regulatory path to complete a pivotal Phase 2 trial of RP-A501 in Danon disease, with 12 male patients set to receive treatment. The trial's co-primary endpoints include myocardial LAMP2 protein expression, a key marker…
- ▹Pivotal Phase 2 path for RP-A501 in Danon disease, but no accelerated approval or surrogate endpoint confirmed
- ▹Gene therapy platform with multiple assets, yet single-asset risk and early-stage commercial potential